- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENZYMATICA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Enzymatica AB: Enzymatica strengthens its management team with commercial and scientific expertise | 338 | GlobeNewswire (Europe) | Enzymatica Enzymatica is strengthening its management team with the addition of Nordic Marketing and Sales Director Joakim Tingström Nordin and Chief Scientist and Head of Production Iceland Bjarki... ► Artikel lesen | |
| 16.07. | Enzymatica AB: Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization | 244 | GlobeNewswire (Europe) | Second quarter· Net sales reached SEK 7,1 (8.3) million.· The operating result totaled SEK -12.6 (-14.9) million.· Earnings per share, basic and diluted, were SEK -0.05 (-0.06).· Cash flow from operating... ► Artikel lesen | |
| 24.06. | Enzymatica AB: The evidence base for ColdZyme remains unchanged - PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme | 181 | GlobeNewswire (Europe) | Enzymatica AB (publ) notes that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the company's placebo-controlled Berlin II study from 2023. The notice... ► Artikel lesen | |
| 09.06. | Enzymatica AB: Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme's continued growth in the Nordics | 631 | GlobeNewswire (Europe) | Enzymatica has appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme's commercial development... ► Artikel lesen | |
| 07.05. | Enzymatica AB: Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026 | 315 | GlobeNewswire (Europe) | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Enzymatica AB (publ) held its annual... ► Artikel lesen | |
| 28.04. | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | 1.133 | GlobeNewswire (Europe) | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| 14.04. | ENZYMATICA AB: Enzymatica publishes annual report for 2025 | 1 | Cision News | ||
| 31.03. | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 901 | GlobeNewswire (Europe) | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | |
| 31.03. | Notice of Annual General Meeting 2026 in Enzymatica AB (publ) | 4 | Cision News | ||
| 18.02. | Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion | 585 | PR Newswire | LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --
Fourth quarterJanuary-December
Net sales reached SEK 18.3 (17.2) millionThe operating result totaled SEK -10.2 (-13.7) million.Earnings... ► Artikel lesen | |
| 11.12.25 | Enzymatica AB: Enzymatica appoints Acting CFO during transition period | 255 | GlobeNewswire (Europe) | Enzymatica today announces the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the... ► Artikel lesen | |
| 20.11.25 | Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance | 416 | GlobeNewswire (Europe) | ColdZyme, the mouth spray developed by Enzymatica AB, has entered into a new partnership with the UK Sports Institute (UKSI) to support the institute's work in promoting athlete health and wellbeing.
The... ► Artikel lesen | |
| 30.10.25 | Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion | 404 | PR Newswire | LUND, Sweden, Oct. 30, 2025 /PRNewswire/ --
Third quarter
January-September
... ► Artikel lesen | |
| 13.10.25 | Enzymatica AB: Enzymatica appoints Holger Lembrér as new CFO | 430 | GlobeNewswire (Europe) | Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team.
Holger... ► Artikel lesen | |
| 01.10.25 | Enzymatica AB: Enzymatica to Support Swedish Biathlon Federation as Official Supplier | 393 | GlobeNewswire (Europe) | Enzymatica is proud to announce a partnership with the Swedish Biathlon Federation, under which Enzymatica becomes an Official Supplier to the national federation.
The collaboration focuses on initiatives... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,170 | -1,09 % | Nicht nur Bayer verdient am Weltmarkt mit, ohne überall selbst präsent zu sein: Ein australischer Psychedelika-Anbieter setzt auf dasselbe Grundprinzip | ||
| NOVO NORDISK | 37,045 | -0,15 % | Novo Nordisk machte GLP-1 zum Milliardenmarkt, CAR-T die Krebsmedizin - welche Biotech-Plattform kommt als Nächstes? | ||
| PFIZER | 23,845 | -0,21 % | Gewinner der Börsengeschichte: +3.923.693 % Rendite und ein Top ESG-Score? Ja, das geht! | © Foto: Frank Rumpenhorst - dpaNachhaltigkeit und eine hohe Rendite schließen sich nicht aus. Im Gegenteil: Diese ESG-Aktie schaffte es unter die Top 30 der US-Aktien mit der höchsten Buy-and-Hold-Rendite... ► Artikel lesen | |
| GILEAD SCIENCES | 124,00 | +0,05 % | Assembly Biosciences, Inc.: Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program | - Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes - - Cash runway remains projected into 2029, including the first... ► Artikel lesen | |
| SANOFI | 73,74 | -0,07 % | BARCLAYS stuft SANOFI auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Sanofi von 79 auf 83 Euro angehoben, aber die Einstufung auf "Equal Weight" belassen. Analyst James Gordon warf... ► Artikel lesen | |
| GSK | 20,640 | -0,05 % | BARCLAYS stuft GSK auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für GSK von 1900 auf 1800 Pence gesenkt und die Einstufung auf "Underweight" belassen. Analyst James Gordon warf am... ► Artikel lesen | |
| ABBVIE | 221,30 | -0,23 % | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | ||
| ASTRAZENECA | 137,45 | -0,51 % | Buy or Goodbye?: Meta, Apple, Rheinmetall und Astrazeneca - Die Analystenstimmen des Tages | © Foto: Julian Stratenschulte/dpa Meta, Apple, Rheinmetall und Astrazeneca: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: US0378331005,DE0007030009,GB0009895292,US30303M1027Den vollständigen... ► Artikel lesen | |
| INNOCAN PHARMA | 1,240 | -0,80 % | Innocan Pharma Corporation: Innocan Pharma Announces Private Placement of Units | HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that... ► Artikel lesen | |
| VIATRIS | 14,252 | +0,07 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| SINOPHARM | 1,708 | 0,00 % | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed... ► Artikel lesen | |
| HALEON | 3,923 | -0,48 % | Haleon Secures Better Shelf Space At Walmart, Target In Bid To Boost Market Share | ||
| LIGAND PHARMACEUTICALS | 254,00 | +3,25 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 6,050 | -0,82 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| PSYCHED WELLNESS | 0,002 | -66,67 % | Psyched Wellness Ltd.: Psyched Wellness Announces Secured Term Loan | Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production... ► Artikel lesen |
Das Unternehmen ENZYMATICA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,154 Euro und damit -5,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZYMATICA AB finden Sie auf Wallstreet Online.